Humanin

Where it comes from. Almost every protein in a human cell is encoded in nuclear DNA. Humanin is not: its open reading frame sits inside the mitochondrial 16S ribosomal RNA gene. It was identified in 2001 by screening a region of an Alzheimer's patient's brain that had survived unusually well, looking for factors that protected neurons against amyloid-beta toxicity [2]. That screen produced a 24-residue peptide nobody had predicted existed.

What it does in models. The unifying activity is cytoprotection, largely through suppression of mitochondrial apoptosis [2]. From that base the literature spreads wide: cardiovascular protection in ischaemia and atherosclerosis models [3], roles in cancer and neurodegenerative disease [4], and a described role in the testis [5].

The mitokine idea. Humanin was the first of a family. MOTS-c followed, with its own metabolic phenotype [6], along with the small humanin-like peptides. These are now framed as mitokines: signals that report mitochondrial stress outward to the cell and the whole organism, and that change with age [1]. That is a real and interesting research programme, and it is where humanin's scientific importance lies.

What is missing. Everything clinical. No trial, no pharmacokinetics, no human safety data, no established dose or route. The observation most often used to justify supplementation - that circulating humanin falls with age - is an association in observational data. Declining levels of something could mean it is protective and being lost, or that it is a stress signal produced less because something upstream has changed. The direction of causation has not been established, and no intervention study exists to settle it.

A caution that follows from the mechanism. Humanin's central activity is blocking apoptosis. Apoptosis is how the body removes damaged and potentially malignant cells. The reviews that discuss humanin in degenerative disease also discuss it in cancer [4], and those are not separate topics - they are two consequences of the same property.

Humanin acts both intracellularly and as a secreted factor. Inside the cell it binds pro-apoptotic Bcl-2 family proteins, notably Bax, preventing their translocation to mitochondria and thereby blocking the intrinsic apoptotic pathway [2]. Extracellularly it has been reported to act through a trimeric receptor complex involving CNTFR, WSX-1 and gp130, and through formyl peptide receptor-like 1, activating STAT3 signalling.

As a mitokine, the framing is that mitochondrial stress increases transcription of the humanin reading frame, and the peptide then signals that stress state to the cell and beyond - a retrograde signal from organelle to nucleus and from tissue to organism [1].

Two honest gaps. First, the receptor pharmacology is less settled than the intracellular Bax interaction, and different papers invoke different receptors. Second, much of the in vivo animal work uses HNG (S14G-humanin), an engineered analogue considerably more potent than the natural peptide [2] - so results attributed to "humanin" often belong to a different molecule.

Supplied as a lyophilised research peptide. Animal studies have used intraperitoneal, intracerebroventricular and intranasal routes; there is no human formulation and no published route selection for human use.

Much of the potent in vivo data uses the S14G analogue rather than native humanin, which is a distinction worth preserving when reading claims about it [2].

There is no human safety data of any kind - no trial, no pharmacokinetics, no case series.

The mechanistic concern worth naming explicitly is the anti-apoptotic one. Blocking mitochondrial apoptosis is protective for a neuron under stress and permissive for a cell that ought to die. The same review literature that covers humanin in degenerative disease covers it in cancer [4], and elevated humanin has been described in some tumour contexts. Nobody has studied what sustained exogenous administration does to cancer risk in any species over a relevant timescale.

A second point: because the natural peptide is cleared quickly and most potent animal data come from an engineered analogue [2], there is no basis for predicting what exposure an injection of native humanin produces or what it would do.

No interaction studies exist. The mechanistically related compound on this site is MOTS-c, another mitochondria-derived peptide, but with a metabolic rather than cytoprotective profile [1][6]. They have never been studied together.